Strategic Collaborations Sisu Pharma's HI-LiTe platform directly targets HSF1 with potential across oncology, neurodegenerative diseases and infections, making them a strong candidate for licensing or co development partnerships with pharma, biotech and academic collaborators. The recent addition of Professor Michael Jung to the Scientific Advisory Board adds credibility for joint research programs and helps attract academic partners and grant opportunities. With a lean team, external collaborations could accelerate go to market plans and de-risk early development.

Oncology Opportunity The focus on therapy resistant cancers addresses a high unmet need and aligns with pharma pipelines seeking new modalities. Sisu's mechanism to degrade HSF1 offers a differentiated approach that can complement existing oncology assets. Potential sales opportunities include early discovery collaborations, biomarker driven studies around HSF1 activity, and licensing negotiations for shared development or regional rights.

Academic Partnerships Based in San Diego with SAB engagement, Sisu Pharma has access to premier cancer biology and bioinformatics resources. This positioning enables collaborative preclinical studies, mechanism work, and model development with leading universities and research institutes, creating pathways to grant funding and publication momentum that can attract partners.

Financing and Deal Readiness The company's revenue and modest funding profile suggests readiness for milestone driven deals with manageable upfront risk. Prospective partners can structure partnerships with upfront research funding followed by milestones tied to readouts in oncology, neurodegeneration or infection programs, enabling phased investment aligned with data generation.

Market Positioning The rising interest in targeted protein degradation and stress response pathways positions Sisu as a differentiator in the biotech landscape. Demonstrating HI-LiTe’s selective HSF1 degradation can be pitched to asset-focused teams seeking novel mechanisms, with San Diego ecosystem advantages and a clear path to co development, licensing or sponsored research.